SCHEMBL24067320

SCHEMBL24067320

CC(=O)c1c(Cl)n(C)c2ccc(Cl)cc12

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.51
BAZ2B Q9UIF8 1/20 0.47
NPC1 O15118 2/20 0.47
MEN1 O00255 1/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
KMT2A Q03164 1/20 0.47
GABRA1 P14867 1/20 0.46
GABRG2 P18507 1/20 0.46
GABRB3 P28472 1/20 0.46
GABRA5 P31644 1/20 0.46
KCNH2 Q12809 1/20 0.46
POLB P06746 1/20 0.46
HTT P42858 1/20 0.46
GFER P55789 1/20 0.46
OXER1 Q8TDS5 8/20 0.44
SRC P12931 1/20 0.44
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22450932 0.85 MAPT (0.48) EGFRNPC1MEN1GAAMAPT
SCHEMBL24067346 0.85 HTT (0.62) EGFRBAZ2BMEN1GAAMAPT
SCHEMBL1923609 0.80 GFER (0.53) EGFRBAZ2BNPC1MEN1GAA
SCHEMBL22450679 0.80 POLB (0.41) EGFRNPC1MEN1GAAMAPT
SCHEMBL4106684 0.79 EGFR (0.68) EGFRNPC1MEN1GAAMAPT
SCHEMBL4117448 0.77 KDM4E (0.51) EGFRBAZ2BMAPTKMT2AGABRA1
SCHEMBL8689660 0.75 GABRA1 (0.48) EGFRBAZ2BMAPTKMT2AGABRA1
SCHEMBL11418784 0.75 GABRA1 (0.48) EGFRBAZ2BMEN1MAPTKMT2A
SCHEMBL28131237 0.74 GFER (0.50) EGFRBAZ2BGAAMAPTPOLB
SCHEMBL1921296 0.73 KDM4E (0.53) BAZ2BMEN1MAPTKMT2AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11358950-B2 SMAC mimetics used as IAP inhibitors and use thereof CHIA TAI TIANGQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2022-06-14 US disclosed
US-20220175917-A1 COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2022-06-09 US disclosed
US-20210371400-A1 SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2021-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220175917-A1 COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR BIRC5, XIAP, BIRC2 EGFR 2998/4885BAZ2B 596/4885NPC1 2017/4885
US-20210371400-A1 SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF BIRC7, BIRC5, BIRC2 EGFR 4121/4885BAZ2B 254/4885NPC1 3131/4885
US-11358950-B2 SMAC mimetics used as IAP inhibitors and use thereof BIRC7, BIRC5, BIRC2 EGFR 4121/4885BAZ2B 254/4885NPC1 3131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.